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ABSTRACT 
AIM: To evaluate the common causes of abnormal vaginal discharge  among 
women of reproductive age group attending a tertiary care hospital using simple 
laboratory techniques and to study the effectiveness of short course intravaginal 
therapy in treating the same. MATERIALS AND METHODS: High vaginal 
swabs were taken from 200 women complaining of abnormal vaginal discharge. 
Bacterial vaginosis was diagnosed by gram stain using Nugent’s criteria, 
candidiasis by gram stain showing budding yeast cells and pseudohyphae, 
trichomoniasis by wet mount showing motility oftrophozoites. Women in whom 
the cause was found were treated with clotrimazole alone for TV and 
candidiasis, clotrimazole and clindamycin(vaginal suppositories for three 
consecutive nights) for those having BV alone or along with the other two 
conditions.RESULTS: Above mentioned simple laboratory techniques 
identified the cause of  abnormal vaginal discharge in 74% patients. Most 
common cause (alone or along with other two causes)was BV in 60% cases, 
candidiasis in 16.5% cases, TV in 10% cases. There was significant association 
between the symptoms, nature, odour, pH of the vaginal discharge and the 
causative organism. The treatment given cured 82.5% cases having BV, 81.8% 
cases havingcandidiasis and 40% cases having trichomoniasis.CONCLUSION: 
Correlating symptomatology with simple laboratory techniques helps to arrive 
at a more accurate diagnosis of abnormal vaginal discharge. Short course 
intravaginal therapy is safe and effective in treating abnormal vaginal discharge 
due to BV and candidiasis but not very effective in trichomoniasis. 
KEYWORDS: “Bacterial vaginosis”, “candidiasis”, “trichomoniasis”, “short 
course”, “intravaginal therapy”, “clotrimazole”, “clindamycin”. 
INTRODUCTION 
      Vaginal discharge is a common gynaecological symptom affecting many 
women. It is a source of considerable discomfort, worry and self-treatment.  
Consultation is often delayed due to embarrassment or fear as many women 
believe sexual transmission plays the main role in causing gynaecological 
symptoms and anything related to sexual transmission is still taboo in 
developing countries like ours. 
 
The treatment of vaginal and cervical infections is quite difficult in 
developing countries as there is scarcity of laboratory facilities for 
identifyingthese infections. WHO promoted the syndromic-based management 
for this reason.1 
 
WHO  syndromic approach is centered on identifying a relatively 
constant group of signs and symptoms (syndrome) and on the awareness of the 
most common organismscausing these conditions and their susceptibility to 
various drugs. Drug regimens were selected to cover the major pathogens 
accountable. The main shortcoming of this approach is the use of oral 
metronidazole in most regimes. Oral metronidazole is associated with nausea, 
vomiting, anorexia in many patients. 
 
 About 10-30% patients treated for BV with oral metronidazole have been 
shown to develop candidiasis later. Less common side effects include dizziness, 
peripheral neuropathy and convulsions as the drug crosses the blood brain 
barrier. These unpleasant side effects and longer duration of treatment (7-
14days) are major factors responsible for non-compliance to treatment. Also to 
be remembered are the risks of change in normal commensal vaginal flora and 
the possibility of emergence of antibiotic resistance.2, 3Hence our study 
evaluated an alternate therapeutic regime not involving oral metronidazole and 
employing a shorter duration of treatment.  
 
Using simple microscopic assessment by Gram’s stain of the vaginal 
smear is emerging as a sensitive non- cultural diagnostic technique for bacterial 
vaginosis 4, 5and candidiasis 5. Direct microscopy (wet mount) of the vaginal 
discharge showing motile Trichomonasvaginalis has been demonstrated to be as 
accurate (in terms of specificity) as culture for diagnosing Trichomoniasis. 
 
  
 
 
 
 
AIM OF THE STUDY 
1. To study the prevalence of Bacterial vaginosis, candidiasis and 
Trichomoniasis in patients complaining of abnormal vaginal discharge in 
the reproductive age group using simple laboratory techniques. 
2. To study the efficacy of short course (3 days) intra-vaginal Clindamycin 
and Clotrimazole therapy in treating the above said 3 conditions. 
 
   
  
 REVIEW OF LITERATURE 
 
BACTERIAL VAGINOSIS 
Bacterial vaginosis (BV) is a polymicrobial syndrome caused by an 
imbalance of the commensal vaginal organisms resulting from the replacement 
of high levels of hydrogen peroxide producing Lactobacillus species by non-
dominant or exogenous bacteria (GIRALDO et al 2007, SCHWEBKE 2009) . 
Along with unpleasant vulvovaginal symptoms and a rise in the vaginal pH 
(usually > 4.5), BV is linked with augmented risks of other complications like 
pelvic inflammatory disease (PID),pregnancy associated complications like 
preterm labour and  postoperative infections. In affected women belonging to 
the high risk group, there is also increased likelihood of acquiring HIV .6, 7 
 
The ecologic dynamics linked to the vaginal microorganisns shift in 
patients affected by BV has not been fully deciphered. It is supposed that with a 
small number of exceptions, BVassociated microbial organisms exist in low 
concentrations in the vaginal flora of normal healthy women (FORSUM et al., 
2005). 
 
 
SYMPTOMATOLOGY: 
Many women suffering with BV are asymptomatic. The most common 
symptom in affected women is a homogenous creamy discharge, associated 
with an offensive odour. Risk factors for BV include African-American race, 
several sex partners, women having sex with women and vaginal douching8. 
Hormone contraceptive pill use, male circumcision and use of condoms 
decrease BV incidence. Though related with earlier age of first sexual 
intercourse and numerous sexual partners, BV is not included under sexually 
transmitted diseases8.  
 
Diagnosis: There is no gold standard test described for BV. In as much as half 
of women who are asymptomatic, cultures show organisms like 
Gardnerellavaginalis. Amsel’s criteria are time and again employed as reference 
standard for evaluating symptomatic women, the best aspirant for a gold 
standard diagnostic test is in all probability Gram stain evaluation by means of  
Nugent’s criteria.9 
 
 
 
 
 
 
 
  
 
Nugent’s Gram stain 
criteria 
Lactobacillus 
morphophytes(large 
gram +ve rods) 
Gardnerella 
and 
Bacteroides 
species 
Morphophytes 
(small gram –
ve rods ) 
Mobiluncus species (Curved 
gram-variable rods) Points 
4+ 0 0 0 
3+ 1+ 1+ or 2+ 1 
2+ 2+ 3+ or 4+ 2 
1+ 3+  3 
0 4+  4 
Points are awarded to the first 3 columns based on microscopic examination. 
To get a final sum, points for all 3 columns are added. 
Score 0-3: negative for BV 
          4-6 : intermediate 
          7-10 : diagnostic for BV 
Source: Nugent et al 1991.9 
 
 
 
 
 
 Gram stain is more unbiased and reproducible by different observers 
compared to wet mount microscopy, having specificity of 70% and sensitivity 
of 93%.10 
Criteria to be employed in research studies for defining normal vaginal 
microbiota and BV  as proposed by the International Working Group on 
Bacterial Vaginosis11:* BV is considered present if Nugent score is  ≥7 or when 
modified Amsel criteria are significantly positive, without regard to symptoms. 
When symptoms are present they must be separately recorded. Abnormal 
symptoms must include, as a minimum, patient's complaint of an increased, foul 
smelling vaginal discharge. 
* Vaginal microflora is considered to be a normal one if Lactobacillus is the 
principal species, in which case, Nugent score is<4. 
Definition of cure of BV11 
Different studies on BV have employed diverse agendas to define 
outcomes of therapy. The Working group was of the general consensus that 
though some classical features of BV recover very fast with therapy (like loss of 
plenty of clue cells), other features take significantly longer time (like vaginal 
pH normalization). Preferably, the evaluation should be taken up after 7 - 10 
days of initiation of treatment, and would help to estimate the cure rate (early 
treatment efficacy). At this evaluation, cure must be defined as lack of 
substantial number of clue cells (<20% of the epithelial cells on wet mount 
microscopy at 100× magnification) or achievement of Nugent score of ≤6; 
Improvement of symptoms must be included, but that would comprise a discrete 
component of therapeutic response. 
 
TREATMENT OPTIONS: 
Metronidazole: 
Metronidazole is a antimicrobial drug belonging to the nitroimidazole 
group, used in management of  protozoal infections like  trichomoniasis as well 
as in anaerobic infections.12 Metronidazole is being widely used in the treating  
BV with good therapeutic results .12Numerous preparations allowing  oral or 
vaginal  administration and various regimens have been  under study. Treatment 
with metronidazole  is complicated by side effects which include 
gastrointestinal symptoms (nausea, vomiting, metallic taste in the mouth) and 
development of candidiasis. Such side effects are being used to substantiate 
single-dose oral metronidazole therapy or topical metronidazole.  
 
 
 
They are also accountable for problems in following a 7 day course of 
treatment and subsequently end up in treatment failure. Inadequate cure will be 
complicated by an augmented risk of disease recurrence and development of 
resistance to metronidazole.13 
 
Clindamycin 
Clindamycin is the next common antimicrobial used for treating BV. It is 
a lincosamide antibiotic, belonging to a larger family of macrolide antibiotics. 
Clindamycin is available in various treatment forms including oral and vaginal 
(ovule and cream). A  study by  Mikamo et al.14 evaluated the oral clindamycin 
vs. intra-vaginal application in treatment of BV. In this study, 450 mg 
clindamycin administered orally thrice a day and 2% clindamycin as vaginal 
cream 5 g once a day, both for a 7 day period, had parallel cure rates. A 
randomized studyby Sobel et al 15compared the efficacy of clindamycin vaginal 
cream (5 g at bedtime for 7 days) with clindamycin vaginal ovules (100 mg 
daily for 3 days) for treating BV. The cure rates were similar. 
 
 
 
 
Clindamycin vs. metronidazole  
According to the CDC BV working group, oral clindamycin (500 mg 
twice daily for 7 days) or topical clindamycin (ovule 100 mg once a day for 3 
days ; 2% clindamycin cream 5 g once daily for 7 days)  appeared to be equally 
effective to oral (500 mg two times a day for 7 days) or topical metronidazole 
(0.75% gel 5 g once a day for 7 days).16 Moreover, it was noted that topical 
clindamycin was more likely to produce  lesser adverse effects (nausea, 
vomiting ,metallic taste in the mouth) compared to oral metronidazole.8 
 
A Cochrane review16 of 24RCTs( randomized controlled trials) in 2009 
concluded that both metronidazole and clindamycin were equally effective,after 
two to three weeks of treatment, achieving proven cure in 92 and 91 percent of 
patients, respectively. 6 RCTs showed oral and topical antibiotics were equally 
active in achieving cure. The main drawback of oral regimens is that a longer 
period of treatment. Intra-vaginal clindamycin cream is preferable in cases of 
intolerance or allergy to metronidazole. Metronidazole  2g single dose has the 
least efficacy for curing bacterial vaginosis and is no longer used or 
recommended. 
 
 
     According to a study by Jorma Paavonen et al17, a 3 day treatment course of 
transvaginal ovules of clindamycin, was as efficacious asandbettertolerated 
thana7 day course oforalmetronidazole 500mg BD,for treating bacterial 
vaginosis. 
 
Newer drug delivery systems: 
Vaginal routes of administration of metronidazole or clindamycin is a 
commonly practised method in the treatment of BV, but their efficacy is 
questionable. Several works have been done so as to improve existing 
preparations or producing new drug delivery systems. A study in Egypt has 
established a hydrogel that swells up in aqueous surroundings for potential use 
as a drug delivery vehicle. This new vaginal drug delivery system for 
metronidazole, has been shown to improve the therapeutic effectiveness as 
compared to that accomplished with the traditional vaginal gel.18 
 
  In addition, new bioadhesive film preparations of clindamycin for 
vaginal administration have been formulated19.Theantibacterial activity and 
properties of these new preparations in vitro may offer a welcome change to 
conventional dosage formulations for topical vaginal application.  
 
The triumph of such novel dosage formulations and bio-adhesive 
productions structured to extend the dwelling time of the drug  in the vagina is 
yet to be evaluated. 
 
Effect of antifungal therapy on BV: 
Self medication with antifungals is a common practice and it may be 
beneficial in women with Candida who are also infected with BV. There is a 
common opinion is that opposing vaginal pH are needed for  growth of  BV and 
C. albicans, but this notion is incorrect as combined infections with BV and 
candida are seen often. Donders et al20 reported that 9 among the 142 women 
(about 6%) with symptomatic candidiasis had concurrent BV. Antifungal 
therapy cured BV in about 70% of women who had simultaneous vulvovaginal 
candidiasis. Also reported was the fact that though antifungal therapy may be 
useful in women with coexisting  BV, it does not prevent BV occurrence in 
women without BV. A similar advantage of antifungal treatment has been 
described in a trial by Sanchez S et al21 in which women receiving ovules 
having both nystatin and metronidazole for BV had superior cure rates at 2 
weeks after therapy compared to those who received metronidazole 0.75% gel 
alone (20% & 4%, respectively).  Also reported was that the benefits of 
combination therapy persisted 3 months after completion of treatment (52% and 
33%, respectively). 
 
Regimens for the treatment of BV according to the US Centre for Disease 
Control22 
Three recommended regimens 
1. Metronidazole 500 mg oral two times a day * 7 days 
2. Metronidazole gel 0.75%, 1 application (5 g) intra-vaginally, once a day* 
5 days 
3. Clindamycin cream 2%, 1 application (5 g) intra-vaginally at bedtime * 7 
days 
Three alternative regimens 
1. Tinidazole 2 g oral OD * 2 days or 1 g oral OD * 5 days 
2. Clindamycin 300 mg oral BD * 7 days 
3. Clindamycin ovules 100mg intra-vaginally once a day * 3 days 
Three recommended regimens for pregnant women 
1. Metronidazole 500 mg oral BD* 7 days 
2. Metronidazole 250 mg oral TDS* 7 days 
3. Clindamycin 300 mg oral BD * 7 days 
 
 
It has been observed from various studies that about 80% of patients treated for 
BV will have a recurrence within one year of treatment. BV can occur and remit 
spontaneously. There is no general agreement on the causes of recurrence of 
BV, and this may explain why some women, even while on adequate therapy, 
do not respond favourably to drugs effective against anaerobic bacteria. 
(GIARLDO et al 2007). The proposed causes include, hygiene habits, number 
of sexual partners, IUCDs, vaginal douches, spermicides, broad spectrum 
antibiotics, frequent sexual intercourse, deficiency of vaginal immune response, 
contamination of lactobacilli with bacteriophages, and the consequent death of 
protective microorganisms (UGWUMADU; TAYLOR- ROBINSON 1997). 
      Regular testing & treatment of sex partners is not required. Treating male 
companions does not decrease relapse rates.23 
 
VULVOVAGINAL CANDIDIASIS 
Candidiasis is the next commonly diagnosed cause of vaginitis after BV. 
Studies show that about 75% of womenfolk will have a candida infection at 
some point of their life and 5% will have repeated episodes.24  Also observed 
is the fact that 10% to 30% of women having no symptoms and with normal 
vaginal flora have positive culture reports for Candida.25-29 On the other hand, 
the percentage of symptomatic women who have positive culture reports is 
20% to 40%30,31 Complications due to VVC are infrequent, but few reports on 
vulvar vestibulitis33 and chorioamnionitis during pregnancy32 require special 
mention. 
Risk factors: Symptomatic VVC is linked to use of condoms and 
diaphragms, contemporary antibiotic therapy, receptive oral sex, use of oral 
contraceptive pills, spermicides, diabetes mellitus and immunosuppressed 
states including AIDS31, 34-37.Though pregnancy is proposed as a risk factor 
for VVC, the prevalence of candida on cultures in pregnant women is 
analogous to that of the non-pregnant population.30 
Symptomatology: In women with cultureresults positive for Candida, the 
most common presenting symptom is pruritus or burning sensation in 
vulva.28 Abnormal vaginal discharge is  reported by majority of women with 
symptomatic VVC. Women may also report a thick, odourless, cottage 
cheese–like discharge. 38 A thick, curdy vaginal discharge mostly points to a 
diagnosis of Candida as it is rarely seen withtrichomoniasis or BV .  
 
A study by Eckert LO et al28concluded that a thick curdy discharge had an 
affirmative predictive value of 84% for diagnosing VVC by culture. On the 
other hand, a thin discharge does not necessarily exclude VVC. On clinical 
examination, vulva and vagina are often erythematous but these findings are 
not specific for VVC. A normal vaginal pH of <4.5 is seen in most cases. 
According to Reed et al30, the accuracy of the clinical examination for VVC 
is quite less in comparison with microscopy and culture.  
Pathogens: Candidaalbicans is the most common reported pathogen in 80% 
to 90% of cases with VVC39.Others have non-albicans species, like C 
glabrata.28Horowitz BJet al and Spinillo A et al40 reported that an increase in 
the non-Candida species to almost 20% in a particular study by the mid-
1990’s may be due to an augmented use of imidazole that are available 
easily over-the-counter. In cases of non-Candida VVC, wet mount results 
are classically negative.28 
Diagnosis of VVC 
1) Direct examination: KOH wet mount or Normal saline 
preparation 
2) Gram Stain: Identification of yeast cells &pseudo hyphae – yeast 
cells are about 4-8microns. Presence of pseudo hyphae indicates 
colonisation & tissue invasion, hence their demonstration in direct 
smear of tissue is highly significant. 
3) Culture: In Sabouraud Dextrose Agar – gold standard: though it 
indicates colonisation, it does not necessarily indicate infection. 
Sensitivity of various diagnostic tests41: 
Wet mount                   : 50-60% 
Wet mount withKOH: 70-80% 
Gram stain                   : 60-70% 
Culture                        : 30-50% 
 
Treatment42: 
General advice 
 Avoiding local irritants e.g. perfumed products 
 Avoiding tight fitting synthetic inner clothing 
Antifungal drugs: 
All oral and topical azole therapies give 80-95% clinical and 
microbiological curein acute vulvo-vaginalcandidiasis in the non-pregnant 
population. Though Nystatin formulations give a 70-90% cure rate, they are not 
routinely used as typically, a14 day course is needed. 
 
Oral regimens: 
 Flucanazole 150mg  stat single dose 
 Itraconazole 200mg BD * 1 day 
 
Intra-vaginal regimes: 
 Clotrimazole vaginal pessary:500mg one dose/100mg OD* 7 days/ 
200mg OD*3days 
 Micanazole vaginal ovule : 1200mg single dose/ 400mg OD * 3 days 
 Econazole vaginal pessary : 150mg single dose 
 
CDC Recommended Regimes for uncomplicated Vulvovaginal Candidiasis 
43: 
 Butoconazole 2% cream  
5 g intra-vaginally OD * 3 days 
 Butoconazole 2% sustained release cream 
5 g intra-vaginally single dose 
 
 Clotrimazole 1% cream 
              5 g intra-vaginally OD *7-14 days 
 Clotrimazole 2% cream 
5 g intra-vaginally OD * 3 days 
 Miconazole 2% cream 
             5 g intra-vaginally OD * 7 days 
 
Thomas B. Lebherz, Larry C. Ford et al44in their study comparing 3 day 
therapy with 200mg clotrimazole  pessaries and 7 day therapy with 100mg 
clotrimazole pessaries found no significant difference in outcome amongst the 
two groups and concluded that short course treatment is more effective and can 
be expected to offer better cure as patient compliance is mainly a function of 
duration of treatment. 
 
 Treatment failure is very rare in VVC. Likely causes include poor 
treatment compliance, wrong diagnosis of initial condition, resistance of 
organisms to conventional treatment, mixed infection, continuous persistence of 
an irritant, recurrence of infection and uncorrected underlying problems 
(diabetes, immunosuppression, concurrent antibiotic use). 
 
  
 
TRICHOMANAS VAGINITIS: 
       Trichomonas vaginalis is the protozoan parasite responsible for 
Trichomonas vaginitis. It is a common sexually transmitted disease. 
 
Non sexual transmission may occur rarely, through dirty towels or 
contaminated water.  
 
The prevalence rate in India is about 6-10%45. Clinical manifestations 
range from asymptomatic to acute signs & symptoms like yellowish green, 
malodourous, often frothy, thin discharge often associated withvulval itching, 
burning & dysuria. Punctate haemorrhages in cervix “strawberry cervix” though 
considered to be  pathognomonic of trichomoniasis, is present in only  2% of 
cases. 46 
 
Complications: 
Complications ofTV include: preterm delivery ( which in turn leads to 
low birth weight and an increase in perinatal mortality) as well as predisposition 
to HIV infection, AIDS, other sexually transmitted diseases and cervical 
cancer.47 
  
 
Infection with TV has also been described infallopian tubes, urinary tract 
and pelvis. TV can cause oral lesions, bronchitis, and pneumonia. Condomsare 
effective at decreasing, but not fully averting transmission. Recent studies 
propose a relationship between TV infection in males and subsequent 
aggressive prostate cancer.  
 
Diagnosis: 
 Wet Mount : Simple office diagnostic procedure – demonstrates jerky 
motility of Trichomonas vaginalis trophozoites : 50-80% 
sensitivity,100% specificity 
 Culture : 75-95% sensitivity – Gold Standard 
 Newer methods:rapid antigen testing, PCR andtranscription-mediated 
amplification – more sensitivity but very costly, not routinely used. 
In a study by Huppert et al48, the sensitivities of wet-mount examination, 
microbiologic culture, rapid antigen detection tests, and nucleic acid 
amplification tests were 51%, 75%, 82%, and 98%, respectively. Specificity 
was close to 100 percent for each method 
 
 
 Treatment43 : 
CDC Recommended regimen : 
 Metronidazole  
  2 g oral single dose  
 Imidazole  
  2 g oral single dose  
Alternative regimen 
 Metronidazole  
  500 mg oral BD *7 days  
Pregnancy 
 Metronidazole 
 
               2 g oral single dose 
Sexual partners must be treated concurrently. To reduce recurrence, 
partners must avoid resuming sexual intercourse till both have concluded 
treatment and are both asymptomatic. 
Clotrimazole has a fungicidal action on dermatophytes, yeasts, and other 
fungi. It also has action on Trichomonasvaginalis and clotrimazole-sensitive 
bacteria. 
      In a multicentre comparison by duBouchet L et al49 of clotrimazole 
vaginal tablets, oral metronidazole, and vaginal pessaries containing 
sulfanilamide, aminacrine hydrochloride, and allantoin for treating  
symptomatictrichomoniasis, it was seen that though oral metronidazole was 
more effective in eradicating TV, reduction of symptoms was seen in all three 
study groups and no side effects were observed in the clotrimazole group as 
compared to the other two groups. It was proposed that Clotrimazole vaginal 
tablets may prove to be an effective alternative to metronidazole in women who 
do not tolerate the unpleasant side effects of metronidazole therapy or in whom 
metronidazole is contraindicated (e.g. First trimester of pregnancy) 
  
 MATERIALS & METHODS 
This study was conducted in the Department of Obstetrics and 
Gynaecology, Raja Mirasudar Hospital, Thanjavur Medical College, Thanjavur. 
 200 married, sexually active women in the reproductive age group (15-
45years) attending the gynaecology outpatient department complaining 
of abnormal vaginal discharge were included in the study.Vaginal 
discharge was classified as abnormal if patients referred to it as the 
main reason for attending the clinic. Informed consent was taken from 
all patients. 
 Patients with bleeding per vaginum, pregnancy, postpartum, post-
menopausal, post-hysterectomy status, those with known genital tract 
malignancies, those who had taken topical/ oral antifungals/ 
antimicrobials in the past one month were excluded from the study.  
 A detailed history was taken with special reference to theduration, 
nature, odour of the vaginal discharge and associated vulval itching, 
lower abdominal pain, dysuria and dyspareunia. History of diabetes, 
prolonged antibiotic use, oral contraceptive use, any symptoms in 
husband were also noted. 
 A speculum examination was performed on each patient, the nature & 
colour of the discharge were noted. pH was measured with the help of 
narrow range pH paper held with forceps and dipped in vaginal 
discharge, taking care to avoid cervical secretions. 
 Two high vaginal swabs were taken from each patient using sterile 
cotton wool vaginal swabs by rubbing and rotating in the posterior 
vaginal fornix. One swab was used immediately to prepare a wet mount 
by adding one or two drops of normal saline on a glass slide and light 
microscopy was used to observe the jerky or darting motility of 
Trichomonas vaginalis.  
 The other swab was sent to the microbiology lab for gram staining and 
reporting.  
 The diagnostic criteria used for microbiological diagnosis were: 
1) Bacterial vaginosis – A Gram’s stain score of >7 based on the scoring 
system by Nugent et al. 
2)  Candidiasis – if gram positive budding yeasts &pseudo hyphae were seen 
on gram’s stain.  
3)  Trichomoniasis – if wet smear microscopy was positive for motile 
Trichomonas vaginalis. 
 
 The  patients diagnosed to have BV alone or in combination with TV or 
candidiasis, were given vaginal suppositories containing a combination of  
Clindamycin 100mg & Clotrimazole 200mg, 3 doses, to be inserted as 
high as possible in the vagina, preferably before retiring to bed on three 
consecutive nights. 
 The  patients diagnosed to have TV alone or candidiasis alone, were 
given vaginal suppositories containing only Clotrimazole 200mg, 3 doses, 
to be inserted as high as possible in the vagina, preferably before retiring 
to bed on three consecutive nights. 
 Those in whom no diagnosis was made were given plac ebo 
medications. 
 Those patients who received antifungal/antimicrobial treatment or a 
combination of both were advised to come for follow up, 7-10days after 
completion of therapy. 
 On the follow up visit, a detailed history taking was done with special 
reference to the symptomatic improvement and any side effects observed 
during treatment. 
 In those patients who were diagnosed to have TV before treatment, wet 
mount examination was done, and in those earlier diagnosed to have BV 
or candidiasis, gram stain was repeated. 
 
OBSERVATION AND RESULTS 
This study was conducted on 200 women presenting with abnormal 
vaginal discharge and the following observations were made. 
 
Among the 200 women, one or more causes of the abnormal vaginal 
discharge were identified in 148 patients. In the remaining 52 patients, no 
diagnosis could be arrived at, using the above defined diagnostic criteria. 
Total number of cases 200 % 
Cause identified 148 74% 
Cause not identified 52 26% 
Table 1 
 
Figure 1 
 
Possible reasons for not identifying cause in 52 cases: 
 Physiological vaginal discharge 
 Cervical infections like Chlamydia, Gonococcus 
 Allergic reactions 
 Viral vaginitis 
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 Inability of the simple laboratory techniques used in the study to 
accurately identify all cases. 
Among the 148 cases in which the cause was identified, bacterial vaginosis 
(BV) alone or along with the other 2 conditions, was seen in 120 patients (60%); 
Trichomonas vaginitis (TV) alone or along with BV was seen in 20 patients 
(10%); and candidiasis alone or with BV  was seen in 33 patients (16.5%). 
Cause No of cases Percentage 
BV alone 95 47.5% 
Candidiasis alone 16 8% 
TV alone 12 6% 
BV & candidiasis 17 8.5% 
BV & TV 8 4% 
No cause identified 52 26% 
Total 200 100% 
Table 2 
 
 
 
 
 
 
 Figure 2  
  
AGE DISTRIBUTION 
The age distribution of patients in our study is as follows: 
Age group No. of cases Percentage 
20-25years 14 7% 
25-30 years 58 29% 
30-35 years 44 22% 
35-40 years 64 32% 
40-45 years 20 10% 
Table 3 
The most common age group of patients in our study was                       
35-40years (32%) 
The mean age of patients was 32.25years. 
 
 
 
 
 
 
 
  
 
 
Figure 3  
 SIGNIFICANT ASSOCIATED SYMPTOMATOLOGY: 
PRURITUS VULVA 
61 of the 200 women (30.5%) included in our study complained of pruritus 
vulva. This was the most common presenting complaint next to abnormal 
vaginal discharge. Other symptoms as told by the patients included lower 
abdominal pain in 24, dysuria in 16, and dyspareunia in 7 cases. 
 
 
Figure 4 
 
 
 
ODOUR OF THE DISCHARGE: 
Of the 200 women included in our study, 112 patients (56%) reported that 
their vaginal discharge was malodourous while the remaining 88 (44%) said that 
there was no odour associated with their vaginal discharge. 
Odour of discharge No. of cases Percentage 
Malodour 112 56% 
No odour 88 44% 
Table 4 
 
 
Figure 5 
COLOUR & NATURE OF THE VAGINAL DISCHARGE: 
        All 200 women included in our study were subjected to speculum 
examination and the colour and nature of the discharge as noted by the clinician 
were classified as homogenous creamy in 139 patients(69.5%), curdy white in 
32 patients(16%), frothy green in 29 patients(14.5%). 
Nature of discharge No. of cases Percentage 
Homogenous creamy 139 69.5% 
Curdy white 32 16% 
Frothy green 29 14.5% 
Table 5 
Homogenous creamy discharge was most common, observed in 139 
patients(69.5%). 
 
 
Figure 6 
pH of the vaginal discharge: 
For all patients in our study, pH of the vaginal discharge was tested using 
narrow range litmus paper held with forceps and dipped into the discharge and 
comparing with the given colour scale. 
pH was < 4.5 in 75 patients (37.5%) and >4.5 in 125 patients (62.5%). 
 
 
Figure 7 
 
 
 
 
 
WET MOUNT EXAMINATION FOR TRICHOMONAS VAGINALIS: 
 
Two high vaginal swabs were taken from all 200 patients in our study. 
One was used to immediately prepare a wet mount using normal saline and 
observed using light microscopy for Trichomonas vaginalis organisms. Of the 
200 studied, 20 patients (10%) were positive for TV. 
 
 
 
Figure 8 
 
 
 
GRAM STAIN FOR BACTERIAL VAGINOSIS: 
Gram staining was done using the second swab in the microbiology 
laboratory. Bacterial vaginosis was scored using Nugent criteria as described 
before. Out of the 200 cases, 120 cases were positive for BV (score 7-10), 30 
cases were in the intermediate group (score 4-6) and 50 cases were negative for 
BV (score 0-3). 
Nugent score No. of cases percentage Interpretation 
7-10 120 60% Positive 
4-6 30 15% Negative 
(intermediate) 
0-3 50 25% Negative 
Table 6 
 
Table 9 
 
 
GRAM STAIN FOR CANDIDA: 
In the same gram stain the presence of candida was also studied. 
Candidiasis was diagnosed when budding yeast cells along with pseudo hyphae 
were observed. Of the 200 cases, 33(16.5%) were positive for candidiasis based 
on the above criteria. 
 
 
 
Figure 10 
 
 
 
 
EVALUATION OF PATIENTS WITH TRICHOMONAS VAGINALIS: 
1. Age distribution : 
Of the 20 patients diagnosed to have Trichomoniasis, the most common age 
group was 35-40years. 
 
 
 
Figure 11 
 
 
 
 
 
 
 
2. Association with pruritus: 
Among the 20 patients with TV, 17 patients (85%) had pruritus vulva and 
this association was statistically significant. 
 
 
Figure 12  
  
Association between Pruritus vulva and TV 
Sl.no Pruritus vulva 
Wet Mount for TV 
Statistical inference Positive 
(n=20) 
Negative 
(n=180) 
1 Present 17(85%) 44(24.4%) 
X2=31.138 
Df=1 
.000<0.05 
Significant 
2 Absent 3(15%) 136(75.6%) 
Table 7 
Statistical test: Chi-square test was used in the above table  
 
Inference:The above table reveals that there is a significant association 
between Pruritus vulva of the patients and TV. Hence, the calculated value less 
than table value (.000<0.05). 
  
  
 
3. Association with Odour of discharge: 
17 (85%) of the 20 patients with TV complained of malodourous 
discharge and this association was statistically significant.   
 
 
Figure 13 
 
 
 
 
 
 
  
Association between odour of the discharge and TV 
Sl.no Odour 
Wet Mount for TV 
Statistical inference Positive 
(n=20) 
Negative 
(n=180) 
1 Malodour 17(85%) 95(52.8%) X2=7.585 
Df=1 
.006<0.05 
Significant 
2 No odour 3(15%) 85(47.2%) 
Table 8 
Statistical test: Chi-square test was used in the above table  
 
Inference:The above table reveals that there is a significant association between 
malodourous discharge of the patients and TV. Hence, the calculated value less 
than table value (.006<0.05). 
 
 
 
 
 
 
  
 
4. Association with nature of the discharge: 
Of the 20 patients with TV, 18(90%) had a frothy green discharge and this 
association was statistically significant. 
 
 
Figure 14  
  
 
Association between nature of the discharge and TV 
Sl.no Nature   
Wet Mount for TV 
Statistical inference Positive 
(n=20) 
Negative 
(n=180) 
1 Homogenous creamy 2(10%) 137(76.1%) X2=102.235 
Df=2 
.000<0.05 
Significant 
2 Curdy white 0 32(17.8%) 
3 Frothy green 18(90%) 11(6.1%) 
Table 8 
Statistical test: Chi-square test was used in the above table  
Inference The above table reveals that there is a significant association between 
frothy green discharge and TV. Hence, the calculated value less than table value 
(.000<0.05). 
 
  
  
5. Association with pH of the discharge: 
        Among the 20 patients with TV, 18(90%) patients had vaginal 
discharge with pH >4.5 and this association was statistically significant. 
 
 
Figure 15  
  
Association between pH of the vaginal discharge and TV 
Sl.no PH 
Wet Mount for TV 
Statistical inference Positive 
(n=20) 
Negative 
(n=180) 
1 Below 4.5 2(10%) 73(406.6%) X2=7.170 
Df=1 
.007<0.05 
Significant 
2 Above 4.5 18(90%) 107(59.4%) 
Table 9 
Statistical test: Chi-square test was used in the abovetable 
 
Inference:The above table reveals that there is a significant association between 
the pH of vaginal discharge being > 4.5 and TV. Hence, the calculated value 
less than table value (.007<0.05). 
 
 
 
 
 
 
  
EVALUATION OF PATIENTS WITH BACTERIAL VAGINOSIS: 
1. Age distribution : 
Of the 120 patients diagnosed to have Bacterial vaginosis, the most common 
age group was 35-40years. 
 
 
Figure 16  
  
 
2. Association with pruritus: 
Among the 120 patients with BV, only 34 patients (28.33%) had pruritus 
vulva while the remaining 86(71.67%) had no pruritus. Hence the association of 
pruritus vulva with BV is not statistically significant.  
 
 
Figure 17  
  
3. Association with Odour of discharge: 
  89 (74.17%) of the 120 patients with BV complained of malodourous 
discharge and this association was statistically significant.I A 
 
 
 
Figure 18  
  
Association between Odour of the discharge and BV 
Sl.no Odour 
Gram stain - BV(Nugent score) 
Statistical inference 7to10 
(n=120) 
4to6 
(n=30) 
0to3 
(n=50) 
1 Malodour 89(74.2%) 10(33.3%) 13(26%) X2=40.591 
Do=2 
.000<0.05 
Significant 
2 No odour 31(25.8%) 20(66.7%) 37(74%) 
Table 10 
Statistical test: Chi-square test was used in the above table  
Inference:The above table reveals that there is a significant association between 
malodour of the discharge and BV. Hence, the calculated value less than table 
value (.000<0.05). 
  
  
 
4. Association with nature of the discharge: 
Of the 120 patients with BV, 99(82.5%) had a homogenous creamy 
discharge and this association was statistically significant. 
 
 
Figure 19  
  
Association between nature of the discharge and BV 
Sl.no Nature  
Gram stain – BV(Nugent score) 
Statistical 
inference 
7to10 
(n=120) 
4to6 
(n=30) 
0to3 
(n=50) 
1 
Homogenous 
creamy 
99(82.5%) 15(50%) 25(50%) X2=24.455 
Do=4 
.000<0.05 
Significant 
2 Curdy white 11 (9.2%) 
7 
(23.3%) 
14 
(28%) 
3 Frothy green 10(8.3%) 8(26.7%) 11(22%) 
Table 11 
Statistical test: Chi-square test was used in the above table  
 
Inference:The above table reveals that there is a significant association between 
homogenous creamy nature of the discharge and BV. Hence, the calculated 
value less than table value (.000<0.05). 
  
  
 
5. Association with pH of the discharge: 
Among the 120 patients with BV, 101(84.17%) patients had vaginal 
discharge with pH >4.5 and this association was statistically significant. 
 
 
Figure 20  
  
 
Association between pH of the discharge and BV 
Sl.no PH 
Gram stain – BV(Nugent score) 
Statistical inference 7to10 
(n=120) 
4to6 
(n=30) 
0to3 
(n=50) 
1 Below 4.5 17(14.2%) 19(63.3%) 39(78%) X2=71.410 
Do=2 
.000<0.05 
Significant 
2 Above 4.5 103(85.8%) 11(36.7%) 11(22%) 
Table 12 
Statistical test: Chi-square test was used in the above table  
Inference:The above table reveals that there is a significant association between 
the pH of vaginal discharge being > 4.5 and BV. Hence, the calculated value 
less than table value (.000<0.05). 
 
 
 
 
 
 
  
 
EVALUATION OF PATIENTS WITH CANDIDIASIS: 
 
1. Age distribution : 
Of the 33 patients diagnosed to have candidiasis, the most common age group 
was 35-40years (10 patients) and an almost equal number (9 patients) were in 
the 25-30years age group and 8 patients in the 30-35years age group. 
 
 
Figure 21 
 
 
 
  
2. Association with pruritus: 
Among the 33 patients with candidiasis, 25patients (75.76%) had 
pruritus vulva and this association was statistically significant. 
 
 
Figure 22 
 
 
 
 
 
 
 
  
 
Association between Pruritus vulva and Candidiasis 
Sl.no Pruritus vulva 
Gram stain - Candida Statistical inference Positive 
(n=33) 
Negative 
(n=167) 
1 Present 25(75.8%) 36(21.6%) X
2=38.188 
Do=1 
.000<0.05 
Significant 
2 Absent 8(24.2%) 131(78.4%) 
Table 13 
Statistical test: Chi-square test was used in the above table  
 
Inference:The above table reveals that there is a significant association between 
Pruritus vulva and Candidiasis. Hence, the calculated value less than table value 
(.000<0.05). 
  
  
3. Association with Odour of discharge: 
20 (60.6%) of the 33 patients with candidiasis complained of 
malodourous discharge and this association was not statistically significant.   
 
 
Figure 23 
 
 
 
 
 
 
 
 4. Association with nature of the discharge: 
Of the 33 patients with candidiasis, 19(82.5%) had a curdy white discharge and 
this association was statistically significant. 
 
 
 
Figure 24 
 
 
 
 
 
 
 
 Association between nature of the discharge and Candidiasis 
Sl.no Nature  
Gram stain- Candida 
Statistical inference Positive 
(n=33) 
Negative 
(n=167) 
1 Homogenous creamy 14(42.4%) 125(74.9%) X2=52.595 
Do=2 
.000<0.05 
Significant 
2 Curdy white 19(57.6%) 13(7.8%) 
3 Frothy green 0 29(17.4%) 
Table 14 
Statistical test: Chi-square test was used in the above table  
Inference:The above table reveals that there is a significant association between 
curdy white nature of the vaginal discharge and Candidiasis. Hence, the 
calculated value less than table value (.000<0.05). 
 
 
 
 
 
 
 
 
  
5. Association with pH of the discharge: 
Among the 33 patients with candidiasis, all (100%) patients had vaginal 
discharge with pH <4.5 and this association was statistically significant. 
 
 
Figure 25 
  
  
Association between pH of the discharge and Candidiasis 
Sl.no PH 
Gram stain - Candida 
Statistical inference Positive 
(n=33) 
Negative 
(n=167) 
1 Below 4.5 33(100%) 42(25.1%) X2=65.868 
Do=1 
.000<0.05 
Significant 
2 Above 4.5 0 125(74.9%) 
Table 15 
Statistical test: Chi-square test was used in the above table  
Inference:The above table reveals that there is a significant association between 
pH of the vaginal discharge being < 4.5 and Candidiasis. Hence, the calculated 
value less than table value (.000<0.05). 
 
  
 EVALUATION OF TREATMENT EFFICACY: 
 Efficacy of treatment in BV : 
Out of the 120 patients diagnosed with BV, 99 patients(82.5%) were cured 
bacteriologically after treatment. 
Symptomatic improvement in the form of complete relief or reduction of 
symptoms was seen in 116 patients. 
 
 
Tables 16 & 17 
 Efficacy of treatment in candidiasis : 
Out of the 33 patients diagnosed with candidiasis, 27 patients (81.8%) 
were cured after treatment. 
Symptomatic improvement in the form of complete relief or reduction of 
symptoms was seen in 27 patients (81.8%). 
 
 
Tables 18 & 19 
 Efficacy of treatment in Trichomonas vaginitis: 
Out of the 20 patients diagnosed with trichomoniasis, 8 patients (40%) 
were cured after treatment. 
Symptomatic improvement in the form of complete relief or reduction of 
symptoms was seen in 11 patients (55%). 
 
 
Tables 20 & 21 
Post treatment status of the 148 patients who were positive for one or two 
of the diseases at the first visit 
 
 
 
  
 
 
 
Of the 148 patients who received treatment, 90% of patients had symptomatic 
relief in the form of complete relief or reduction of symptoms. 
 
 
 
  
  
DISCUSSION 
      In our study, 200 women of the reproductive age group presenting with 
abnormal vaginal discharge to the gynaecology OPD were studied and 
etiological diagnosis was arrived at in 148 patients. Rekha et al50 in their study 
involving similar diagnostic criteria, included 203 patients & established the 
diagnosis in 146 patients. Other studies by French et al51, Ryan et al52, Moherdal 
et al53were concurrent with our study, showing that in 10-58% of women 
presenting with vaginal discharge, no diagnosis could be reached using the 
diagnostic methods under consideration. 
 
      The common age group of patients in our study was 35-40years. In other 
studies by Rekha et al50, Ryan et al52, Thulkar et al5, Sharma et al54, the most 
common age group was 25-30 years. This observation may be a reflection of the 
later age at marriage and sexual intercourse in the community or due to 
hesitation of the younger age group in our community to come out with these 
problems. 
 
 
 
 
In our study, the most common cause of abnormal vaginal discharge in 
the reproductive age group was Bacterial vaginosis (60%). This is in accordance 
to various studies: Thulkar et al – 37.5%.,  Renu et al55 – 36.4%, Bhalla. P et 
al56 – 32.8%, Sumati AH et al57 – 58.4%. The differences in incidence of 
bacterial vaginosis may be due to the type of population under study and the 
prevalence in the population studied. 
 
     Next to the abnormal vaginal discharge, pruritus vulva was the most 
common presenting complaint in patients (30.5%) in our study. Similar finding 
was also noted in the study by Rekha et al50. 
 
     Bacterial vaginosis was associated with malodourous vaginal discharge in 
74.2% of cases, a homogenous creamy discharge in 82.5% of cases and a pH of 
> 4.5 in 84.5% of cases and all these associations were statistically significant. 
 
     Candidiasis was associated with pruritus in 75.8% cases, a curdy white 
discharge in 82.5% cases and pH < 4.5 in 100% cases and all these associations 
were statistically significant. 
 
 
 
Trichomoniasis was associated with malodourous vaginal discharge in 
85% of cases,  pruritus in 85% cases, a  frothy green discharge in 90% of cases 
and pH > 4.5 in 90% of cases and all these associations were statistically 
significant. 
 
 Studies by Rekha et al50, French et al51, Sanchez et al58, Rao et al5 in 
accordance to our study showed that nature of the vaginal discharge may be a 
useful criterion in differentiating the common causes of vaginal discharge.  
 
 From our study we can infer the most probable cause of the vaginal 
discharge by correlating the nature, odour, pH of the discharge and association 
with pruritus. For example, a malodourous homogenous creamy discharge with 
pH > 4.5, is most probably due to bacterial vaginosis. A malodourous, frothy 
green discharge associated with pruritus and a pH > 4.5 is most probably due to 
Trichomoniasis. A curdy white discharge of pH < 4.5 associated with pruritus 
but without any odour, is most probably due to Candidiasis. In concurrence to 
studies by Rao et al5, French et al51, Moherdaul et al53 and Vishwanath et al2, 
these  
findings help in the syndromic management of abnormal vaginal discharge, 
especially in developing countries where appropriate facilities for diagnosing 
the exact cause are not available.  
 
In our study, the efficacy of clotrimazole (200mg) and clindamycin 
(100mg) short course (3 days) intra-vaginal therapy in achieving 
microbiological cure was 79% (117 of the 148 treated patients) and 
symptomatic cure was 90% (133 of the 148 patients who were treated).  
 
The difference in the microbiological cure and symptomatic improvement 
may be due to the belief of the patients that the treatment given to them will 
surely cure their condition and hence their perceived improvement of symptoms 
even when actual cure is not established. 
 
     The cure rate for Bacterial vaginosis in our study is 82.5% (99 of the 
120 treated patients). Faro S et al59 observed cure rates of 73.7% in their study 
on effectiveness of clindamycin vaginal preparations in BV.  Studies by 
Mikamo et al14 showed similar cure rates for oral & vaginal clindamycin in 
treatment of BV. According to the recent Cochrane review16, cure rates in BV 
were similar for oral clindamycin, topical  
clindamycin, oral metronidazole and topical metronidazole. Donders et al20 
reported that antifungal therapy cured simultaneously BV in 70% patients in 
their study. Sanchez S et21 al reported that combined antifungal and 
metronidazole topical therapy achieved better cure rates in BV than 
metronidazole alone. Taking into consideration all the above data and quoting 
the cure rates achieved by our treatment we could suggest that intra-vaginal 
clindamycin & clotrimazole short course therapy is a safe and effective alternate 
to the traditional 7-14 day oral metronidazole therapy. 
Our treatment acquired 81.8% cure rates in candidiasis. This is in 
accordance to observations of the Clinical Effectiveness Group22 that both 
vaginal & oral azoles have similar cure rates of 80-95% in vulvovaginal 
candidiasis. 
 In our study, the cure rate for Trichomoniasis was only 40%            (8 
out of 20). This is in accordance to the study by duBouchet L et al49 who 
observed cure rates of only 12% for vaginal clotrimazole compared to 80% for 
oral metronidazole. So it can be recommended that though our short course 
intra-vaginal therapy is effective in the other two conditions, patients in whom 
trichomoniasis is diagnosed or strongly suspected based on clinical symptoms 
and observations should preferably be given oral metronidazole. 
 
 
SUMMARY 
Abnormal vaginal discharge is a common complaint of many patients 
attending the gynaecologyoutpatient department. 
        The most common age group of patients in the study was 35-40years. 
        Using simple laboratory techniques like wet mount saline microscopy and 
gram staining identified the cause in 74% patients. 
        Bacterial vaginosis was the most commonly identified cause in 60% 
patients, followed by candidiasis in 16.5% and trichomoniasis in 10%. 
       Pruritus vulva was the next common complaint to vaginal discharge seen in 
30.5% patients. 
       The association of Bacterial vaginosis with a malodourous, homogenous 
creamy discharge with a pH >4.5 was statistically significant. 
         The association of candidiasis with pruritus and a curdy white vaginal 
discharge of pH < 4.5 was statistically significant. 
         The association of trichomoniasis with pruritus, a malodourous frothy 
green vaginal discharge and a pH >4.5 was statistically significant. 
 
 
Short course (3 days) intra-vaginal clotrimazole (200mg) and 
clindamycin (100mg) was effective in curing bacterial vaginosis and candidiasis 
in more than 80% of patients. But the cure rate for trichomoniasis was only 
40%. 
          Symptomatic improvement was seen in a higher proportion of patients 
(90%) than actual microbiological cure. 
 
  
CONCLUSION 
 Abnormal vaginal discharge is a common complaint in women of the 
reproductive age group. It is the role of the clinician to conclude if the discharge 
is physiological or pathological and arrive at a proper diagnosis before 
institution of treatment. 
 
 In a resource constrained setting, the addition of simple office diagnostic 
tests like wet mount saline microscopy and gram staining can aid in arriving at a 
more accurate diagnosis than what is reached by symptomatology and clinical 
examination alone. 
 
Short course intra-vaginal therapy for three days employing 200mg 
clotrimazole and 100mg clindamycin is a safe and effective alternative to oral 
antimicrobial therapy for treatment of abnormal vaginal discharge especially in 
patients with side effects or intolerance to oral preparations and in those with 
poor compliance to longer duration of therapy as there is always the problem of 
drug resistance developing in the community due to inadequate treatment. 
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PROFORMA 
 
NAME       : 
 
 
AGE          : 
 
 
OP NO      : 
 
 
SOCIOECONOMIC STATUS  : 
 
 
PRESENTING COMPLAINTS: 
 
VAGINAL DISCHARGE : 
 
DURATION : 
 
NATURE : 
 
     HOMOGENOUS CREAMY           □ 
  
      CURDY WHITE                             □ 
 
      FROTHY GREEN   □ 
 
     PRURITUS VULVA    :      
 
 
 
  DYSURIA                    :     
 
 
 
 DYSPAREUNIA         :      
 
 
 
MENSRUAL HISTORY : 
 
   CYCLES 
 
   L.M.P: 
 
 
 
 
 
□ Yes 
□ No 
□ Yes 
□ No 
□ Yes 
□ No 
 
 
MARITAL HISTORY : 
 
MARRIED SINCE  
 
ANY SYMPTOMS IN HUSBAND 
 
OBSTETRIC HISTORY : 
 
NO. OF CHILDREN 
 
MODE OF DELIVERY 
 
 LAST CHILD BIRTH 
 
 
PAST HISTORY: 
 
DIABETES 
 
HISTORY S/O STD 
 
 PROLONGED ANTIBIOTIC THERAPY 
 
 OCP USE 
 
 
CLINICAL EXAMINATION : 
 
  GENERAL CONDITION 
 
  PER ABDOMEN 
 
  PER SPECULUM 
 
             CERVIX & VAGINA -     □  HEALTHY 
 
- □CONGESTED 
 
- □EROSION 
 
 
NATURE OF VAGINAL DISCHARGE  
 
HOMOGENOUS CREAMY   :  □ 
 
CURDY WHITE                      : □ 
 
FROTHY GREEN                   : □ 
 
 
     PH:     □< 4.5             □> 4.5 
 
 
PER VAGINAL EXAMINATION: 
 
 
 
 
 
WET MOUNT FOR TRICHOMONAS VAGINALIS :□ positive    □ negative 
 
 
GRAM STAIN FOR BACTERIAL VAGINOSIS: 
 
Nugent score :□   0-3 
□   4-6 
□   7-10 
 
GRAM STAIN FOR CANDIDA:         □ positive    □ negative 
 
 
 
 
TREATMENT GIVEN : 
 
 
 
 
FOLLOW UP VISIT: 
 
     WET MOUNT FOR TRICHOMONAS VAGINALIS:□ positive    □ negative 
 
 
     GRAM STAIN FOR BACTERIAL VAGINOSIS: 
 
             Nugent score :□   0-3 
□   4-6 
□   7-10 
 GRAM STAIN FOR CANDIDA:   □ positive    □ negative 
 
 
 
□ Yes 
□ No 
 
SYMPTOMATIC RESPONSE: 
 
□COMPLETE RELEIF  
 
□REDUCTION OF SYMPTOMS 
 
□NO IMPROVEMENT 
 
□WORSENING OF SYMPTOMS 
 
 
 S.NO 
Name Age  OP no. Pruritus vulva Odour Nature pH 
I-
TV 
 I - 
BV 
I - 
Candida 
 II- 
TV 
II - 
BV 
II - 
Candida 
Symptomatic 
Improvement 
1 Dhanakodi 42 121005 2 1 1 2 2 1 2 0 3 2 1 
2 Shanthi 37 113008 1 2 1 1 2 2 2 0 0 0 0 
3 Nirmala 35 121685 1 1 1 2 2 1 2 0 3 2 1 
4 Parimala 27 121045 2 2 1 2 2 1 2 0 3 2 1 
5 Hemalatha 34 121056 2 1 1 2 2 1 2 0 2 2 1 
6 Dhanam 25 121055 1 1 1 2 2 1 2 0 3 2 1 
7 Durgadevi 27 121076 2 1 1 2 2 1 2 0 3 2 2 
8 Revathy 28 121097 2 2 1 2 2 1 2 0 2 2 1 
9 Devika 37 121103 2 2 3 2 2 2 2 0 0 0 0 
10 Sumathy 35 121089 1 1 3 2 1 3 2 2 0 0 1 
11 Ganga 35 121301 1 1 1 2 2 1 2 0 3 2 1 
12 Suseela 30 121322 2 1 1 1 2 2 2 0 0 0 0 
13 Umapathy 27 121324 1 2 1 2 2 2 2 0 0 0 0 
14 Radhiga 29 121318 2 1 1 2 2 1 2 0 3 2 1 
15 Pushparani 35 121365 2 2 1 2 2 1 2 0 2 2 2 
16 Rajamani 37 121347 2 1 1 2 2 1 2 0 2 2 1 
17 Anandhavalli 35 110986 2 1 1 2 2 1 2 0 3 2 1 
18 Meenakshi 30 112993 1 1 3 2 1 3 2 1 0 0 4 
19 Shanthi 30 111451 1 1 1 1 2 2 2 0 0 0 0 
20 Thamaraiselvi 25 112994 2 2 1 1 2 2 2 0 0 0 0 
21 Kolanji 35 113111 1 1 2 1 2 1 1 0 3 2 1 
22 Sathyaprabha 24 112482 2 1 1 2 2 1 2 0 2 2 2 
23 Amudha 40 113000 2 2 3 2 2 2 2 0 0 0 0 
24 Prabha 24 112479 2 2 1 2 2 1 2 0 2 2 2 
25 Janaki 38 127637 1 2 3 1 2 3 2 0 0 0 0 
26 Rajeshwari 38 123667 2 1 1 2 2 1 2 0 2 2 1 
27 Faritha 37 110911 1 1 3 2 1 3 2 1 0 0 3 
28 Andal 30 110923 2 2 1 2 2 3 2 0 0 0 0 
29 Lakshmi 34 110987 1 1 1 2 1 1 2 2 1 1 2 
30 Pattu 40 127634 1 1 1 1 2 1 1 0 3 2 1 
31 Alamelu 32 127705 2 2 1 1 2 3 2 0 0 0 0 
32 Mahendramani 35 127742 2 2 2 1 2 3 2 0 0 0 0 
33 Kolanji 28 127746 2 2 2 1 2 2 2 0 0 0 0 
34 Chinnapulla 42 127745 2 2 1 2 2 2 2 0 0 0 0 
35 Jaicy Rose 37 127001 2 1 1 2 2 1 2 0 3 2 1 
36 Samiyammal 38 127018 2 1 3 2 1 2 2 1 0 0 3 
37 Karpagavalli 39 127020 2 2 3 1 2 2 2 0 0 0 0 
38 Sathyadevi 33 127057 2 1 1 2 2 1 2 0 3 2 1 
39 Chinnaponnu 35 127075 2 1 2 1 2 1 1 0 2 2 1 
40 Jenita 27 127071 2 2 1 2 2 1 2 0 2 2 2 
41 Poongodhai 40 127091 2 1 1 1 2 3 2 0 0 0 0 
42 Valli 36 127138 2 2 1 2 2 1 2 0 3 2 2 
43 Selvambal 34 127203 2 1 1 2 2 1 2 0 3 2 2 
44 Rajeshmary 30 127216 2 1 1 2 2 1 2 0 3 2 2 
45 Anuradha 29 127226 2 2 1 2 2 2 2 0 0 0 0 
46 Mariyamma 27 127561 1 1 1 1 2 2 1 0 0 1 4 
47 Muthurasu 43 127564 2 2 3 1 2 3 2 0 0 0 0 
48 Selvi 35 127367 1 1 3 1 1 2 2 2 0 0 1 
49 Malliga 40 127353 1 1 1 2 2 1 2 0 3 2 2 
50 Chinnamal 44 127374 2 2 1 1 2 2 2 0 0 0 0 
51 Mahalakshmi 23 127370 2 1 1 2 2 1 2 0 3 2 2 
52 Maheshwari 26 127371 2 1 1 2 2 1 2 0 3 2 2 
53 Revathy 35 127373 2 2 1 2 2 1 2 0 2 2 1 
54 Vijayakala 31 134579 2 1 1 2 2 1 2 0 3 2 1 
55 Sumathy 29 134591 2 2 1 2 2 1 2 0 3 2 1 
56 Palaniyayi 25 134580 2 1 1 2 2 1 2 0 3 2 1 
57 Amudha 28 134616 2 1 1 2 2 1 2 0 3 2 1 
58 Valli 28 134629 1 2 1 1 2 3 1 0 0 1 3 
59 Madhiyalagi 35 134658 1 1 3 2 1 1 2 1 1 2 3 
60 Thenmozhi 30 134745 2 1 3 2 1 3 2 2 0 0 1 
61 Dhanalaksmi 30 134773 2 1 1 2 2 1 2 0 3 2 2 
62 Jayalakshmi 39 134791 2 1 1 2 2 1 2 0 3 2 1 
63 Rukmani 37 134822 2 2 1 1 2 1 1 0 2 2 2 
64 Chitravalli 25 134812 2 2 1 2 2 3 2 0 0 0 0 
65 Lusiamary 31 134798 2 1 3 1 2 3 2 0 0 0 0 
66 Sandiradevi 32 136194 1 1 2 1 2 1 1 0 3 2 2 
67 Jayalakshmi 35 136243 2 1 1 2 2 1 2 0 2 2 1 
68 Mary 32 136455 2 2 1 1 2 3 2 0 0 0 0 
69 Manjula 32 140018 1 2 2 1 2 1 1 0 1 2 2 
70 Chitra 27 140007 2 1 2 1 2 1 1 0 2 2 2 
71 Vasuki 35 136500 1 1 1 1 2 1 1 0 3 2 1 
72 Sathyarani 27 140024 2 1 1 2 2 3 2 0 0 0 0 
73 Hema 33 140262 2 2 3 1 2 3 2 0 0 0 0 
74 Malliga 38 140252 1 2 3 2 1 3 2 1 0 0 3 
75 Thamaraiselvi 36 140253 2 1 1 2 2 1 2 0 3 2 1 
76 Sumathy 37 140266 2 1 1 2 2 1 2 0 2 2 1 
77 Thenmozhi 30 140269 2 1 1 2 2 1 2 0 3 2 1 
78 Chitra 28 140284 1 1 1 1 2 1 1 0 3 2 1 
79 Vijaya 24 140281 2 1 1 2 2 1 2 0 3 2 1 
80 Chitradevi 29 140498 2 2 1 1 2 3 2 0 0 0 0 
81 Mythili 23 140509 2 2 1 2 2 3 2 0 0 0 0 
82 Rani 26 146711 2 1 1 2 2 1 2 0 3 2 1 
83 Arayee 34 146776 1 2 1 2 2 1 2 0 1 2 1 
84 Poovatha 37 145879 1 1 3 2 1 2 2 1 0 0 2 
85 Dhanam 24 146876 2 1 1 2 2 1 2 0 2 2 1 
86 Firoz Begam 27 147109 2 1 1 2 2 1 2 0 3 2 1 
87 Manjula 34 147137 1 1 2 1 2 3 1 0 0 1 3 
88 Deepa 25 147169 2 2 2 1 2 2 2 0 0 0 0 
89 Priya 27 147108 2 2 1 2 2 1 2 0 1 2 1 
90 Kanagavalli 28 147205 2 1 1 2 2 1 2 0 3 2 2 
91 Anbuselvi 37 147356 2 2 2 2 2 2 2 0 0 0 0 
92 Barathy 35 147326 1 1 1 2 1 1 2 2 3 2 1 
93 Janaki 35 147346 2 1 1 2 2 1 2 0 2 2 2 
94 Parvathy 30 147492 1 2 1 1 2 3 1 0 0 2 2 
95 Lyla 27 147501 2 1 1 2 2 1 2 0 2 2 2 
96 Vanathi 29 147525 2 1 1 2 2 1 2 0 1 2 1 
97 Leelavathy 35 147547 1 1 3 1 1 3 2 1 0 0 4 
98 anbarasi 37 147552 1 1 1 2 2 1 2 0 3 2 1 
99 Kirutniga 35 147587 2 1 2 1 2 1 1 0 3 2 1 
100 Mohana 29 147599 2 2 1 1 2 3 2 0 0 0 0 
101 Kamala 42 148616 2 2 1 2 2 1 2 0 2 2 1 
102 Vaidegi 28 147814 2 1 1 2 2 1 2 0 3 2 1 
103 Meenakshi 27 147823 2 2 2 1 2 2 2 0 0 0 0 
104 Subha 34 147827 1 1 3 2 1 1 2 2 3 2 1 
105 Rajeshwari 42 147831 2 1 1 2 2 1 2 0 2 2 2 
106 Prabha 27 147833 2 1 1 2 2 1 2 0 1 2 1 
107 gomathy 43 147839 2 2 2 2 2 2 2 0 0 0 0 
108 Kala 35 147841 2 2 1 2 2 1 2 0 3 2 1 
109 Surya 40 147841 1 1 2 1 2 1 1 0 2 2 1 
110 Ramani 44 147856 1 1 3 2 1 1 2 1 2 2 3 
111 Saranya 23 147859 2 2 1 2 2 1 2 0 3 2 2 
112 Prema 26 147860 2 2 1 1 2 3 2 0 0 0 0 
113 Pushpavalli 35 147864 2 1 1 2 2 1 2 0 3 2 2 
114 Susaiyammal 31 147872 2 1 1 2 2 1 2 0 2 2 2 
115 Patturoja 29 147881 2 2 1 1 2 3 2 0 0 0 0 
116 Niroja 25 147895 1 1 1 1 2 3 1 0 0 2 1 
117 Karunapathy 28 147900 2 2 1 2 2 1 2 0 1 2 2 
118 Tamilpriya 28 147907 1 1 1 2 2 1 2 0 2 2 1 
119 Amudha 35 148911 2 2 1 1 2 3 2 0 0 0 0 
120 Amsu 30 148916 2 2 3 2 2 1 2 0 1 2 1 
121 Parvathy 30 148922 2 1 1 2 2 1 2 0 3 2 2 
122 Kokila 39 148928 1 2 3 2 1 2 2 1 0 0 2 
123 Mariyam 37 148938 2 2 1 2 2 1 2 0 3 2 1 
124 Rajam 25 148946 2 1 1 2 2 3 2 0 0 0 0 
125 Kavitha 31 148953 1 2 2 1 2 3 1 0 0 2 2 
126 Geetha 23 148961 2 1 1 2 2 1 2 0 1 2 2 
127 Lakshmi 35 148968 2 1 1 2 2 1 2 0 2 2 2 
128 Dharmambal 35 148972 1 2 1 2 2 1 2 0 3 2 1 
129 Dhamayanthi 24 148986 2 1 1 2 2 1 2 0 1 2 2 
130 Janani 40 148991 1 2 2 1 2 3 1 0 0 1 3 
131 Shobana 24 148999 1 1 1 1 2 1 1 0 3 2 1 
132 Rajakumari 38 149007 2 1 1 2 2 1 2 0 2 2 1 
133 Gnansundari 38 149015 2 2 1 2 2 1 2 0 3 2 1 
134 Parimala 37 149025 2 1 1 2 2 1 2 0 1 2 1 
135 Kamatchi 30 149036 1 2 1 1 2 3 1 0 0 2 1 
136 Parveen 34 149039 2 1 1 2 2 1 2 0 2 2 2 
137 Rekha 40 149047 1 1 3 2 1 1 2 1 3 2 3 
138 hemavathy 32 149059 2 2 1 2 2 1 2 0 1 2 1 
139 Kannagi 35 149061 2 2 2 1 2 3 2 0 0 0 0 
140 Saralmary 28 140069 2 1 2 1 2 3 1 0 0 2 1 
141 Tamilselvi 42 149071 1 2 2 1 2 1 1 0 2 2 1 
142 Vimala 37 149078 2 1 3 2 2 1 2 0 3 2 1 
143 Sivasakthi 38 149083 2 1 1 2 2 1 2 0 2 2 1 
144 Solaiammal 39 149087 1 2 1 1 2 2 1 0 0 2 2 
145 Sangeetha 33 149092 2 1 3 2 1 2 2 2 0 0 1 
146 Kamala 35 149097 2 2 1 1 2 3 2 0 0 0 0 
147 Kala 27 149116 1 2 1 2 2 1 2 0 2 2 1 
148 Nisha 40 149122 2 1 1 1 2 3 2 0 0 0 0 
149 Durgadevi 36 149134 2 1 1 2 2 1 2 0 3 2 1 
150 Vasanthi 34 149143 1 1 1 2 2 1 2 0 1 1 1 
151 Bhuvana 30 149149 2 2 1 2 2 1 2 0 3 2 2 
152 Radhiga 29 149153 2 2 2 1 2 2 2 0 0 0 0 
153 Angayarkanni 27 149167 2 1 2 1 2 1 1 0 2 2 2 
154 Rameshwari 43 149174 2 1 1 2 2 1 2 0 1 2 1 
155 Kanmani 35 149182 1 1 1 1 2 2 1 0 0 2 1 
156 Suseela 40 149191 2 1 1 2 2 1 2 0 3 2 2 
157 Punitha 44 148199 2 2 1 1 2 3 2 0 0 0 0 
158 Deeparani 31 149205 2 2 1 2 2 1 2 0 1 2 1 
159 Malar 29 149216 2 2 2 1 2 3 1 0 0 2 1 
160 Jothi 25 149229 1 1 3 2 1 1 2 1 2 2 3 
161 Saritha 28 149236 2 1 1 1 2 2 2 0 0 0 0 
162 Chellam 28 149237 2 1 1 2 2 1 2 0 3 2 1 
163 Baby 35 149248 1 1 2 1 2 1 1 0 2 2 1 
164 Renuka 30 149251 2 2 1 2 2 1 2 0 2 2 2 
165 Chinnamani 30 149269 1 2 3 2 1 3 2 1 0 0 2 
166 Santha 39 149273 1 2 2 1 2 3 1 0 0 2 1 
167 Gowri 37 149285 2 1 1 2 2 1 2 0 3 2 2 
168 Radha 25 149290 2 2 2 1 2 2 2 0 0 0 0 
169 Anusiya 31 149297 2 2 2 1 2 3 2 0 0 0 0 
170 Deepika 20 149301 2 1 1 2 2 1 2 0 1 1 1 
171 Thavaselvi 35 149309 2 1 1 2 2 1 2 0 2 2 1 
172 Deepa 32 149317 1 1 2 1 2 1 1 0 1 2 2 
173 Hema 32 149327 2 2 2 1 2 3 2 0 0 0 0 
174 Ramya 27 149329 2 1 1 2 2 1 2 0 3 1 1 
175 Divya 35 149333 1 2 1 2 2 1 2 0 2 2 1 
176 Deivanai 27 149348 1 1 1 1 2 2 1 0 0 1 4 
177 Sasikala 33 149351 2 2 1 1 2 2 2 0 0 0 0 
178 Selvambal 38 149368 2 1 1 2 2 1 2 0 3 2 1 
179 Pattu 36 149372 2 1 1 2 2 1 2 0 3 2 2 
180 Paapathy 37 149382 2 2 1 1 2 3 2 0 0 0 0 
181 Rogini 30 149399 1 1 1 2 2 1 2 0 1 2 1 
182 Gomathy 28 149404 2 2 2 1 2 3 2 0 0 0 0 
183 Rasathi 24 149411 2 1 1 1 2 1 1 0 1 2 2 
184 Thilagavathy 29 149426 1 2 3 2 2 1 2 0 2 2 1 
185 Janaki 23 149438 2 1 1 2 2 1 2 0 3 2 1 
186 Parvathy 26 149447 2 2 1 1 2 3 2 0 0 0 0 
187 Sumathy 34 149458 1 2 2 1 2 3 1 0 0 2 1 
188 Isaiyasari 37 149457 2 1 1 2 2 1 2 0 1 2 1 
189 Tamilselvi 24 149469 1 2 3 2 2 1 2 0 2 2 2 
190 Mohana 27 149471 2 2 1 1 2 2 2 0 0 0 0 
191 Parimala 34 149483 2 1 1 2 2 1 2 0 2 2 2 
192 Kalaiyarasi 25 149496 2 2 1 1 2 3 2 0 0 0 0 
193 Rekha 27 149507 1 1 3 2 1 1 2 2 3 2 1 
194 Pottamal 28 149511 1 2 1 2 2 1 2 0 2 2 1 
195 Saradhambal 37 149527 2 2 2 1 2 3 2 0 0 0 0 
196 Kannagi 35 149538 1 2 2 1 2 3 1 0 0 1 3 
197 Jeyanthi 35 149549 2 1 1 2 2 1 2 0 3 2 1 
198 Paapa 30 149558 2 2 1 2 2 1 2 0 3 2 1 
199 Jenmaragini 27 149560 2 2 1 1 2 3 2 0 0 0 0 
200 Malliga 29 149579 2 2 1 1 2 3 2 0 0 0 0 
 
